Tag: cse:lxx
March 23, 2020
Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment
Lexaria Bioscience has expanded the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp. March 19, 2020
Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program
Lexaria Bioscience is commencing a program to study the benefits of Lexaria's DehydraTECHTM drug delivery platform in the fight against... March 17, 2020
Lexaria Bioscience Announces Warrant Issuance
Lexaria Bioscience Corp. announces that on March 16, 2020 it issued share purchase warrants to one of its Canadian-based consultants. March 5, 2020
Lexaria Provides Update on Two Licensed Clients
Lexaria Bioscience has successfully processed its first DehydraTECHTM-enabled liquid nanoemulsion for CBD beverages for one of its licensed clients. February 13, 2020
Industry Solutions from Lexaria’s DehydraTECH(TM) Hemp and Cannabis Powders
Lexaria Bioscience Corp. announces that its DehydraTECH(TM)-enabled CBD infused powders are now available for sale across the USA. January 22, 2020
Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category
Lexaria announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology to Cannadips' cannabis products. January 14, 2020